Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia

Purpose Little is known regarding the trend of polypharmacy in Asia. We used data from 5 Asian countries to examine the patterns of antidepressant (AD) prescription and trends of psychotropic polypharmacy over time. Methods We used the cross-sectional, pharmacoepidemiological data from 2004 and 2013 REAP-AD (Research on Asian Psychotropic Prescription Patterns for Antidepressants) to examine the patterns of AD prescriptions in clinical settings in China, Japan, Korea, Singapore, and Taiwan. We compared the trend in polypharmacy (ie, concomitant use of ≥2 classes of psychotropic) among individuals receiving AD prescriptions in 2004 and 2013 using multivariable logistic regression models in different diagnostic categories. Results The proportion of patients with psychotropic polypharmacy decreased from 2004 to 2013 in all 3 diagnostic categories, including mood disorders (adjusted odds ratio [aOR], 0.44 [0.35–0.56]; P < 0.001), anxiety disorders (aOR, 0.58 [0.36–0.94]; P = 0.028), and psychotic disorders (aOR, 0.18 [0.05–0.60]; P = 0.006). Among individuals with AD prescriptions, concomitant use of anxiolytics (including sedative-hypnotics) decreased in patients with mood disorders (aOR, 0.34 [0.27–0.42]; P < 0.001) and anxiety disorders (aOR, 0.43 [0.27–0.67]; P < 0.001). In contrast, concomitant use of antipsychotics in patients with mood disorders increased (aOR, 1.43 [1.15–1.77]; P = 0.001), and concomitant use of mood stabilizers in patients with psychotic disorders also increased (aOR, 3.49 [1.50–8.14]; P = 0.004). Conclusions This is the first study examining trends in psychotropic polypharmacy in East Asia. We found a generally decreasing trend of psychotropic polypharmacy in contrast to the increasing trend reported from Western countries. These findings could offer significant implications for health system reform or policy making.

[1]  C. Schneider,et al.  Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study , 2017, British journal of clinical pharmacology.

[2]  S. Kanba,et al.  A comparison of clinical characteristics of older adults treated with antidepressants in general and psychiatric hospitals in Asia , 2017, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[3]  S. Kim,et al.  Trends in the prescription of benzodiazepines for the elderly in Korea , 2017, BMC Psychiatry.

[4]  H. Möller,et al.  Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines , 2017, International journal of psychiatry in clinical practice.

[5]  S. Kanba,et al.  Clinical Use of Mood Stabilizers With Antidepressants in Asia: Report From the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Projects in 2004 and 2013 , 2017, Journal of clinical psychopharmacology.

[6]  G. Waldemar,et al.  Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. , 2017, Journal of Alzheimer's disease : JAD.

[7]  S. Kanba,et al.  Factors Associated With Antidepressant Dosing in Asia: Findings From the Research on Asian Psychotropic Prescription Study , 2016, Journal of clinical psychopharmacology.

[8]  S. Normand,et al.  Ten-Year Trends in Quality of Care and Spending for Depression , 2016 .

[9]  S. Kanba,et al.  International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: A 10‐year comparison study , 2015, Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists.

[10]  Andrew T Chan,et al.  Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. , 2015, JAMA.

[11]  H. Fang,et al.  Consolidating the social health insurance schemes in China: towards an equitable and efficient health system , 2015, The Lancet.

[12]  R. Mojtabai,et al.  Antidepressant use in 27 European countries: Associations with sociodemographic, cultural and economic factors , 2015, British Journal of Psychiatry.

[13]  Y. Kao,et al.  Effects of drug guidelines on prescriptions of benzodiazepine and non-benzodiazepine under National Health Insurance System , 2015 .

[14]  Maudsley Nhs Trust,et al.  The Maudsley Prescribing Guidelines in Psychiatry , 2015 .

[15]  S. Tanihara The Proportion of Uncoded Diagnoses in Computerized Health Insurance Claims in Japan in May 2010 According to ICD-10 Disease Categories , 2014 .

[16]  Richard A Armstrong,et al.  When to use the Bonferroni correction , 2014, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[17]  R. Magnezi,et al.  Off-Label Use of Sodium Valproate for Schizophrenia , 2014, PloS one.

[18]  Liang-Jen Wang,et al.  Trends in anxiolytic-hypnotic use and polypharmacy in Taiwan, 2002-2009: a nationwide, population-based survey. , 2014, Psychiatric services.

[19]  M. Olfson,et al.  National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. , 2014, The Journal of clinical psychiatry.

[20]  W. K. Kennedy,et al.  Clinically Significant Drug Interactions with Atypical Antipsychotics , 2013, CNS Drugs.

[21]  P. Masand,et al.  Second-generation antipsychotics in the treatment of major depressive disorder: current evidence , 2013, Expert review of neurotherapeutics.

[22]  M. Alda,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. , 2013, Bipolar disorders.

[23]  N. Shah,et al.  Polypharmacy In Psychiatry: A Review , 2013, Mens sana monographs.

[24]  J. Moncrieff,et al.  Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. , 2012, The British journal of psychiatry : the journal of mental science.

[25]  P. Souverein,et al.  Reimbursement Restriction and Moderate Decrease in Benzodiazepine Use in General Practice , 2012, The Annals of Family Medicine.

[26]  S. Normand,et al.  Ten-year trends in quality of care and spending for depression: 1996 through 2005. , 2011, Archives of general psychiatry.

[27]  Mark Olfson,et al.  Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. , 2011, Health affairs.

[28]  M. Olfson,et al.  National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[29]  V. Joshi,et al.  Health insurance in Singapore: who's not included and why? , 2010, Singapore medical journal.

[30]  C. Andrade,et al.  Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications , 2010, Mens Sana Monographs.

[31]  H. Möller,et al.  The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[32]  M. Olfson,et al.  National trends in psychotropic medication polypharmacy in office-based psychiatry. , 2010, Archives of general psychiatry.

[33]  R. Mojtabai Americans' attitudes toward psychiatric medications: 1998-2006. , 2009, Psychiatric services.

[34]  Keh‐ming Lin,et al.  The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[35]  Daniel M. Hartung,et al.  Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. , 2008, The Journal of clinical psychiatry.

[36]  R. Baldessarini,et al.  Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. , 2007, British journal of clinical pharmacology.

[37]  R. Yoshimura,et al.  Valproic Acid improves Psychotic Agitation without Influencing Plasma Risperidone Levels in Schizophrenic Patients , 2007, Pharmacopsychiatry.

[38]  M. Thase Bipolar Depression: Issues in Diagnosis and Treatment , 2005, Harvard review of psychiatry.

[39]  C. Barbui,et al.  Antidepressant drug use in Lombardy, Italy: a population-based study. , 2004, Journal of affective disorders.

[40]  S. Heckers,et al.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. , 2004, British journal of clinical pharmacology.

[41]  P. Mitchell,et al.  Length of Therapy with Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in Australia , 2004, The Australian and New Zealand journal of psychiatry.

[42]  P. Mitchell,et al.  Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. , 2004, Australian and New Zealand journal of psychiatry (Print).

[43]  B. Bégaud,et al.  Antidepressants: psychiatrists' opinions and clinical practice , 2003, Acta psychiatrica Scandinavica.

[44]  R. Nagata,et al.  Japanese pharmaceutical and regulatory environment , 2002, Dialogues in Clinical Neuroscience.

[45]  K. Kroenke,et al.  Polypharmacy and medication adherence: small steps on a long road. , 2001, Journal of general internal medicine.

[46]  K. Kroenke,et al.  Polypharmacy and medication adherence , 2001, Journal of General Internal Medicine.

[47]  P. Goodnick,et al.  Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology , 1998, Journal of psychopharmacology.

[48]  B. Pollock,et al.  Newer antidepressants and the cytochrome P450 system. , 1996, The American journal of psychiatry.

[49]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.